Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analyses from the Phase 2 PATHFINDER Study With 2-Year Follow-Up

被引：0

作者：

Gotlib, Jason ^{[1
]}

Reiter, Andreas ^{[2
]}

Radia, Deepti H. ^{[3
]}

Deininger, Michael W. ^{[4
]}

George, Tracy I. ^{[5
]}

Panse, Jens ^{[6
]}

Vannucchi, Alessandro M. ^{[7
]}

Platzbecker, Uwe ^{[8
]}

Alvarez-Twose, Ivan ^{[9
]}

Mital, Andrzej ^{[10
]}

Hermine, Olivier ^{[11
,12
]}

Dybedal, Ingunn ^{[13
]}

Hexner, Elizabeth O. ^{[14
]}

Span, Lambert ^{[15
]}

Mesa, Ruben ^{[16
]}

Bose, Prithviraj ^{[17
]}

Pettit, Kristen M. ^{[18
]}

Oh, Stephen T. ^{[19
,20
]}

Lin, Hui-Min ^{[21
]}

Dimitrijevic, Sasa ^{[22
]}

Munoz-Gonzalez, Javier I. ^{[22
]}

DeAngelo, Daniel J. ^{[23
]}

机构：

[1] Stanford Univ, Sch Med, Stanford Canc Inst, Div Hematol, Stanford, CA USA

[2] Heidelberg Univ, Dept Hematol & Oncol, Mannheim, Germany

[3] Guys & St Thomass NHS Fdn Trust, London, England

[4] Versiti Blood Res Inst, Milwaukee, WI USA

[5] Univ Utah, ARUP Labs, Salt Lake City, UT USA

[6] Rhein Westfal TH Aachen, Univ Hosp Aachen, Med Fac, Dept Oncol Hematol Hemostaseol & Stem Cell Transp, Aachen, Germany

[7] Univ Florence, Azienda Osped Univ Careggi, CRIMM, Ctr Res & Innovat Myeloproliferat Neoplasms, Florence, Italy

[8] Univ Leipzig, Leipzig, Germany

[9] Inst Mastocytosis Studies Castilla La Mancha, Spanish Reference Ctr Mastocytosis, Toledo, Spain

[10] Med Univ Gdansk, Dept Hematol & Transplantol, Gdansk, Poland

[11] Univ Paris, Necker Enfants Malad Hosp, APHP, Dept Hematol,CEREMAST, Paris, France

[12] Univ Paris, INSERM U1163, Imagine Inst, Paris, France

[13] Oslo Univ Hosp, Dept Hematol, Oslo, Norway

[14] Univ Penn, Abramson Canc Ctr, Philadelphia, PA USA

[15] Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands

[16] UT Hlth San Antonio MD Anderson, Mays Canc Ctr, San Antonio, TX USA

[17] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[18] Univ Michigan, Div Hematol Oncol, Ann Arbor, MI USA

[19] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[20] Washington Univ, Sch Med, St Louis, MO USA

[21] Blueprint Med Corp, Cambridge, MA USA

[22] Blueprint Med Switzerland GmbH, Zug, Switzerland

[23] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

MPN; systemic mastocytosis; tyrosine kinase inhibitor; c-kit; phase II;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MPN-295

引用

页码：S388 / S389

页数：2

共 20 条

[1] Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analysis From the Phase 2 PATHFINDER Study With 3-Year Follow-up
Reiter, Andreas
Gotlib, Jason
Radia, Deepti H.
Alvarez-Twose, Ivan
Deininger, Michael W.
George, Tracy I.
Panse, Jens
Pettit, Kristen M.
Vannucchi, Alessandro M.
Platzbecker, Uwe
Hermine, Olivier
Elshoury, Amro
Livideanu, Christina Bulai
Mesa, Ruben
Ustun, Celalettin
Triggiani, Massimo
Dybedal, Ingunn
Jurcic, Joseph
Zanotti, Roberta
Span, Lambert F.
Oh, Stephen T.
Yacoub, Abdulraheem
Hexner, Elizabeth O.
Bose, Prithviraj
Lee, Stephanie
Sperr, Wolfgang R.
Griffiths, Elizabeth A.
Butler, Matthew
Bidollari, Ilda
Lin, Hui-Min
Rylova, Svetlana
Munoz-Gonzalez, Javier I.
DeAngelo, Daniel J.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S425 - S426
[2] Efficacy and Safety of ≤200 mg Avapritinib in Patients with Advanced Systemic Mastocytosis: Pooled Results from the Phase 1 EXPLORER and Interim Phase 2 PATHFINDER Studies
Radia, Deepti
DeAngelo, Daniel
Deininger, Michael W.
Reiter, Andreas
Sen, Jayita
Lin, Hui Min
Dimitrijevic, Sasa
Gotlib, Jason
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S367 - S368
[3] Safety and Efficacy of Bezuclastinib (CGT9486), a Novel, Highly Selective, Potent KIT D816V Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis (AdvSM): Results From Part 1 of the Phase 2 Apex Trial
Vachhani, Pankit
Tashi, Tsewang
Schiller, Gary
Lee, Stephanie
Piris-Villaespesa, Miguel
Pomares, Helena
Livideanu, Cristina Bulai
Lambert, Jonathan
Hunter, Anthony M.
George, Tracy I.
Patel, Jay
DeAngelo, Daniel J.
Papayannidis, Cristina
Shoumariyeh, Khalid
Exter, Ben
Sun, Lei
Zhang, Jenna
Cable, LouAnn
Pilla, Amanda
Jolin, Hina A.
Easton, Rachael
Carden, Marcus
Pullarkat, Vinod
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S429 - S430
[4] Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study
Briani, Chiara
Argyriou, Andreas A.
Izquierdo, Cristina
Velasco, Roser
Campagnolo, Marta
Alberti, Paola
Frigeni, Barbara
Cacciavillani, Mario
Bergamo, Francesca
Cortinovis, Diego
Cazzaniga, Marina
Bruna, Jordi
Cavaletti, Guido
Kalofonos, Haralabos P.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2014, 19 (04) : 299 - 306
[5] Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101
Tomita, Y.
Motzer, R. J.
Choueiri, T. K.
Rini, B., I
Miyake, H.
Uemura, H.
Albiges, L.
Fujii, Y.
Umeyama, Y.
Wang, J.
Mariani, M.
Schmidinger, M.
ESMO OPEN, 2022, 7 (02)
[6] Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study
Ono, Takaaki
Hino, Masayuki
Matsumura, Itaru
Fujisawa, Shin
Ishizawa, Kenichi
Sakaida, Emiko
Sekiguchi, Naohiro
Ono, Chiho
Aizawa, Mana
Tanetsugu, Yusuke
Koide, Yuichiro
Takahashi, Naoto
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2022, 116 (06) : 871 - 882
[7] Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study
Takaaki Ono
Masayuki Hino
Itaru Matsumura
Shin Fujisawa
Kenichi Ishizawa
Emiko Sakaida
Naohiro Sekiguchi
Chiho Ono
Mana Aizawa
Yusuke Tanetsugu
Yuichiro Koide
Naoto Takahashi
International Journal of Hematology, 2022, 116 : 871 - 882
[8] Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma
Nakaigawa, Noboru
Tomita, Yoshihiko
Tamada, Satoshi
Tatsugami, Katsunori
Osawa, Takahiro
Oya, Mototsugu
Kanayama, Hiroomi
Miura, Yuji
Sassa, Naoto
Nishimura, Kazuo
Nozawa, Masahiro
Masumori, Naoya
Miyoshi, Yasuhide
Kuroda, Shingo
Kimura, Akiko
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2023, 28 (03) : 416 - 426
[9] Final efficacy and safety results and biomarker analysis of a phase 2 study of cabozantinib in Japanese patients with advanced renal cell carcinoma
Noboru Nakaigawa
Yoshihiko Tomita
Satoshi Tamada
Katsunori Tatsugami
Takahiro Osawa
Mototsugu Oya
Hiroomi Kanayama
Yuji Miura
Naoto Sassa
Kazuo Nishimura
Masahiro Nozawa
Naoya Masumori
Yasuhide Miyoshi
Shingo Kuroda
Akiko Kimura
International Journal of Clinical Oncology, 2023, 28 : 416 - 426
[10] Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting
Inoue, Kenichi
Takahashi, Masato
Mukai, Hirofumi
Yamanaka, Takashi
Egawa, Chiyomi
Sakata, Yukinori
Ikezawa, Hiroki
Matsuoka, Toshiyuki
Tsurutani, Junji
INVESTIGATIONAL NEW DRUGS, 2020, 38 (05) : 1540 - 1549

← 1 2 →